Want to see SE:ANNX full AI Analyst Report?
Annexin Pharmaceuticals AB (ANNX) Financial Statements
Annexin Pharmaceuticals AB Financial Overview
Annexin Pharmaceuticals AB's market cap is currently $57.89M. The company's EPS TTM is $-4.40; its P/E ratio is -1.51; Annexin Pharmaceuticals AB is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ -48.00K | $ -193.00K | $ -193.00K | $ -193.00K | $ -192.00K |
| Operating Income | $ -36.31M | $ -50.48M | $ -44.18M | $ -40.72M | $ -51.23M |
| EBITDA | $ -36.84M | $ -50.20M | $ -43.86M | $ -40.72M | $ -50.28M |
| Net Income | $ -36.89M | $ -50.25M | $ -44.05M | $ -40.73M | $ -52.14M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 27.39M | $ 16.34M | $ 21.41M | $ 31.11M | $ 49.48M |
| Total Assets | $ 30.16M | $ 19.04M | $ 26.76M | $ 36.68M | $ 52.79M |
| Total Debt | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Net Debt | $ -27.39M | $ -16.34M | $ -21.41M | $ -31.11M | $ -49.48M |
| Total Liabilities | $ 5.22M | $ 5.32M | $ 7.95M | $ 6.53M | $ 6.06M |
| Stockholders' Equity | $ 24.93M | $ 13.71M | $ 18.81M | $ 30.15M | $ 46.73M |
| Cash Flow | |||||
| Free Cash Flow | $ -37.05M | $ -50.23M | $ -43.40M | $ -41.16M | $ -45.02M |
| Operating Cash Flow | $ -36.92M | $ -50.23M | $ -43.40M | $ -41.16M | $ -45.02M |
| Investing Cash Flow | $ -129.00K | $ 0.00 | $ 96.00K | $ -260.00K | $ 0.00 |
| Financing Cash Flow | $ 48.11M | $ 45.15M | $ 33.61M | $ 23.06M | $ 76.37M |
Currency in SEK